Aviragen Therapeutics (AVIR) Tops Q4 EPS by 3c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• Top Wealth Group expects net profit to double in fiscal 2026